Why the study?
Whether to continue or stop renin-angiotensin system inhibitors before major surgery remains unresolved, leading to conflicting guidelines.
Does continuation of renin-angiotensin system inhibitors compared to discontinuation reduce major complications in patients undergoing major non-cardiac surgery?
Does continuation of renin-angiotensin system inhibitors compared to discontinuation reduce major complications in patients undergoing major non-cardiac surgery?
This trial protocol outlines a study to determine whether continuing or stopping RAS inhibitors before major non-cardiac surgery affects the rate of major postoperative complications.
No takes yet. Share an insight, caveat, or question.
Optimal perioperative RAS inhibitor management remains uncertain; this RCT will deliver direct evidence on continuation versus discontinuation.
Legrand et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: